Table 2.
Evidence overview of silodosin 8 mg versus tamsulosin 0.2–0.4 mg
| Outcome | No. of trials (evaluated) | Intervention, % (n/N) or mean | Control, % (n/N) or mean | Results and magnitude of effect (95% CI) | Strength of evidence |
|---|---|---|---|---|---|
| Responders, based on ≥25% reduction in total I-PSS score from baseline | 3 (1283) | 72 (456/632) | 68 (440/651) | Similar between groups: RR 1.07 (0.91–1.26) |
Moderatea |
| I-PSS score, mean change from baseline | 8 (1598) | −8.2 points | −7.5 points | Similar between groups: WMD −0.52 (−1.58 to 0.54) |
Moderatea |
| I-PSS QoL, mean change from baseline | 6 (788) | −1.7 points | −1.4 points | Similar between groups: WMD −0.20 (−0.72 to 0.32) |
Moderatea |
| Overall withdrawals | 4 (1125) | 9 (53/563) | 9 (49/562) | Similar between groups: RR 1.05 (0.73–1.5) |
Lowa,b |
| Withdrawals due to adverse effects | 3 (1222) | 5 (30/601) | 3 (16/621) | Greater with silodosin: RR 1.96 (1.04–3.71) |
Moderatea |
| Participants with ≥1 adverse effect | 3 (1338) | 52 (342/659) | 46 (314/679) | RR 1.11 (0.95–1.29) | Insufficient |
CI = confidence intervals; I-PSS = International Prostate Symptom Score; QoL = quality of life; RR = risk ratio; WMD = weighted mean difference.
Downgraded based on the following:
a
Risk of bias (moderate).
b
Imprecision.